Advances in non-nicotine pharmacotherapy for smoking cessation

被引:34
作者
Covey, LS
Sullivan, MA
Johnston, JA
Glassman, AH
Robinson, MD
Adams, DP
机构
[1] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA
[3] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[4] Cabarrus Family Med Residency Program, Concord, NC USA
[5] E Tennessee State Univ, James Quillen Sch Med, Dept Family Med & Publ Hlth, Johnson City, TN 37614 USA
关键词
D O I
10.2165/00003495-200059010-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Progress in understanding the pharmacological nature of tobacco addiction, along with the modest success rates achieved by the nicotine replacement therapies, has provided the major impetus for the development of non-nicotine drugs as smoking cessation aids. This article reviews evidence from controlled trials of several non-nicotine medications for the treatment of nicotine dependence. Clonidine was the first non-nicotine medication to show efficacy for smoking cessation in multiple studies, but its effect was found to be limited at best. Positive results across several trials have been consistent-ly demonstrated for amfebutamone (bupropion). Encouraging results have also been observed for nortriptyline and moclobemide. Studies of combined treatments using non-nicotine medications (amfebutamone, mecamylamine, oral dextrose) with nicotine replacement therapy suggest increased efficacy relative to treatments using one or the other treatment strategy alone. Thus, available evidence indicates that non-nicotine drug treatments offer a promising panoply of therapeutic strategies for the addicted smoker.
引用
收藏
页码:17 / 31
页数:15
相关论文
共 81 条
[1]  
BALDESSARINI RJ, 1984, ARCH GEN PSYCHIAT, V41, P103
[2]   Sensitization of the mesoaccumbens dopamine response to nicotine [J].
Balfour, DJK ;
Benwell, MEM ;
Birrell, CE ;
Kelly, RJ ;
Al-Aloul, M .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1998, 59 (04) :1021-1030
[3]   A REVERSIBLE MONOAMINE-OXIDASE-A INHIBITOR (MOCLOBEMIDE) FACILITATES SMOKING CESSATION AND ABSTINENCE IN HEAVY, DEPENDENT SMOKERS [J].
BERLIN, I ;
SAID, S ;
SPREUXVAROQUAUX, O ;
LAUNAY, JM ;
OLIVARES, R ;
MILLET, V ;
LECRUBIER, Y ;
PUECH, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :444-452
[4]   Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers [J].
Berlin, I ;
SpreuxVaroquaux, O ;
Said, S ;
Launay, JM .
DRUG AND ALCOHOL DEPENDENCE, 1997, 45 (1-2) :31-37
[5]   THE FUNCTIONAL-ROLE OF MONOAMINE OXIDASE-A AND OXIDASE-B IN THE MAMMALIAN CENTRAL-NERVOUS-SYSTEM [J].
BERRY, MD ;
JUORIO, AV ;
PATERSON, IA .
PROGRESS IN NEUROBIOLOGY, 1994, 42 (03) :375-391
[6]  
CADA DJ, 1996, DRUG FACTS COMPARISO, P1453
[7]  
CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P989
[8]   RELAPSE PREVENTION STRATEGIES FOR THE TREATMENT OF COCAINE ABUSE [J].
CARROLL, KM ;
ROUNSAVILLE, BJ ;
KELLER, DS .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 1991, 17 (03) :249-265
[9]   A PLACEBO-CONTROLLED EVALUATION OF THE EFFECTS OF BUSPIRONE ON SMOKING CESSATION - DIFFERENCES BETWEEN HIGH-ANXIETY AND LOW-ANXIETY SMOKERS [J].
CINCIRIPINI, PM ;
LAPITSKY, L ;
SEAY, S ;
WALLFISCH, A ;
MEYER, WJ ;
VANVUNAKIS, H .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1995, 15 (03) :182-191
[10]  
CINCIRIPINI PM, 1998, ONCOLOGY, V12, P1